These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20555331)

  • 1. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T; Sasaki J; Biro S; Kono S; Otonari T; Ikeda Y;
    Hypertens Res; 2010 Sep; 33(9):886-91. PubMed ID: 20555331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
    Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
    J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
    Weir MR; Hollenberg NK; Remuzzi G; Zappe DH; Meng X; Parving HH
    J Hypertens; 2011 Oct; 29(10):2031-7. PubMed ID: 21841500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC; Ayala DE; Fontao MJ; Mojón A; Fernández JR
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial.
    Menne J; Farsang C; Deák L; Klebs S; Meier M; Handrock R; Sieder C; Haller H
    J Hypertens; 2008 Sep; 26(9):1860-7. PubMed ID: 18698222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic.
    Takami T
    Hypertens Res; 2009 Dec; 32(12):1086-90. PubMed ID: 19779491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J; Greulich T; Reinke C; Koehler U; Vogelmeier C; Becker HF; Schmidt AC; Canisius S
    Curr Med Res Opin; 2010 Aug; 26(8):1925-32. PubMed ID: 20560730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.